Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells

Xiaolong Wei(Shantou University), Mazhar Adli(University of Virginia), Harun Öztürk(Northwestern University), Anindya Dutta(Indian Institute of Technology Bombay), Patrick E. O’Hara(University of Virginia), Cem Kuscu(University of Tennessee Health Science Center), Ebru Yilmaz(University of Virginia), Alaa Habieb(University of Virginia), Jiekun Yang(Rutgers, The State University of New Jersey), Sara J. Adair, Kyung Yong Lee(University of Virginia), Todd W. Bauer(University of Virginia), Denis Liu(University of Virginia), William J. Kane(Mayo Clinic in Arizona), Yusuf Mert Demirlenk(WinnMed)
Proceedings of the National Academy of Sciences
October 23, 2020
Cited by 113


Related Papers